1,019 filings
Page 15 of 51
8-K
16s0eyw
21 Jan 20
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
10:09am
8-K
zt8ev o1m
13 Jan 20
Trovagene Oncology Investor Presentation January 2020
10:22am
4
t8tduii
3 Jan 20
Trovagene / Mark Erlander ownership change
4:15pm
4
tq8l k7jdvx7o
3 Jan 20
Trovagene / Mark Erlander ownership change
4:10pm
8-K
v9u3qw51cwr lwl
9 Dec 19
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH
2:49pm
8-K
6yo5k8kh yaqf
4 Dec 19
Other Events
12:15pm
424B3
40mohhfdfwgim2tafa
14 Nov 19
Prospectus supplement
12:14pm
8-K
lksu8j
14 Nov 19
Other Events
9:07am
EFFECT
oinm5 0amqsckyr
14 Nov 19
Notice of effectiveness
12:15am
UPLOAD
mly6evasv pcl
12 Nov 19
Letter from SEC
12:00am
CORRESP
ze995eqx3t73u rt
12 Nov 19
Correspondence with SEC
12:00am
8-K
zrx5mcz1pvh7zy1
7 Nov 19
Trovagene Announces Third Quarter 2019 Results and Highlights
4:21pm
8-K
o7cch797 64ye
6 Nov 19
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
12:41pm
SC 13G
05kt tjx37w1
4 Nov 19
Trovagene, Inc.
12:00am
SC 13G
relt 2ap9a8qsatmwrg
1 Nov 19
Trovagene, Inc.
4:10pm
D
ibhkz
30 Oct 19
$5M in equity / options / securities to be acquired, sold $5M, 2 investors
4:51pm